Impact of a Pharmacist-driven Methicillin-resistant Staphylococcus aureus Polymerase Chain Reaction Nasal Swab Protocol on the De-escalation of Empiric Vancomycin in Patients with Pneumonia in a Rural Healthcare Setting
Precious Dadzie, Tyson Dietrich, John Ashurst, Precious Dadzie, Tyson Dietrich, John Ashurst
Abstract
Introduction Pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) carries a high rate of morbidity and mortality. Many clinicians empirically treat those at risk of developing MRSA pneumonia with vancomycin. Several studies have identified a high negative predictive value of the MRSA polymerase chain reaction (PCR) nasal swab test in lower respiratory tract infections, suggesting it can be used to guide the de-escalation of empiric anti-MRSA therapy. Objective To evaluate the impact of a pharmacist-driven MRSA PCR nasal swab protocol on the de-escalation of empiric vancomycin in patients with pneumonia in a rural healthcare setting. Secondarily, to assess the rate of hospital length of stay, the rate of vancomycin-associated acute kidney injury, and in-hospital mortality after pharmacist-driven de-escalation of empiric vancomycin in patients with pneumonia. Methods A retrospective, single-center, pre-post cohort study was conducted in patients after the implementation of a pharmacist-driven protocol allowing pharmacists to obtain nasal swabs and PCR testing for MRSA in those on empiric vancomycin therapy for suspected MRSA pneumonia. Based on negative test results, pharmacists recommended a de-escalation of empiric vancomycin to the physician. Patients were included if they were adults at least 18 years of age, had a physician diagnosis of suspected or confirmed pneumonia, and initiated on at least one dose of intravenous vancomycin within 48 hours of admission. Results A total of 79 patients were identified for inclusion in the pre-protocol group (n=32) or post-protocol group (n= 47). The mean duration of vancomycin therapy in the pre-protocol group was 3.1 days as compared to 1.7 days in the post-protocol group for a 1.4 days reduction (p=0.044). There was no significant impact on the number of vancomycin cases de-escalated within 24 hours (p=0.14) but there was a significant reduction at 48 hours (p=0.01). Protocol implementation was associated with a reduction in the average length of hospitalization (8 versus 5.20 days, p=0.006). Neither group had a vancomycin-associated acute kidney injury or in-hospital mortality. Conclusion Among patients with suspected MRSA pneumonia, a pharmacist-driven MRSA PCR nasal swab protocol resulted in a significant reduction of empiric vancomycin duration of therapy without an adverse impact on clinical outcomes in a rural healthcare setting.
Keywords: antibiotic stewardship; mrsa; pneumonia.
Conflict of interest statement
The authors have declared that no competing interests exist.
Copyright © 2019, Dadzie et al.
References
- Deaths: final data for 2015. Murphy SL, Xu J, Kochanek KD, Curtin SC, Arias E. Natl Vital Stat Rep. 2017;66:1–75.
- Anti-microbial resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for the Disease Control and Prevention, 2011-2014. Weiner LM, Webb AK, Limbago B, et al. Infect Control Hosp Epidemiol. 2016;37:1288–1301.
- Pneumonia caused by methicillin-resistant Staphylococcus aureus. Rubinstein E, Kollef MH, Nathwani D. Clin Infect Dis. 2008;46:378–385.
- Morbidity and cost burden of methicillin resistant Staphylococcus aureus in early onset ventilator associated pneumonia. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Crit Care. 2006;10:97.
- Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Kalil AC, Metersky ML, Klompas M, et al. Clin Infect Dis. 2016;63:61.
- Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Mandell LA, Wunderink RG, Anzueto A, et al. Clin Infect Dis. 2007;44:27–72.
- Methicillin-resistant Staphylococcus aureus nares colonization at hospital admission and its effects on subsequent MRSA infection. Davis KA, Steward JJ, Crouch HK, Florez CE, Hospenthal DR. Clin Infect Dis. 2004;39:776–782.
- Predictive value of methicillin-resistant Staphylococcus aureus nasal swab PCR assay for MRSA pneumonia. Dangerfield B, Chung A, Webb B, Seville MT. Antimicrob Agents Chemother. 2014;58:859–864.
- Prediction of methicillin-resistant Staphylococcus aureus involvement in disease sites by concomitant nasal sampling. Robicsek A, Suseno M, Beaumont J, Thomson RB Jr, Peterson LR. J Clin Microbiol. 2008;46:588–592.
- The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. Parente DM, Cunha BC, Mylonakis E, Timbrook TT. Clin Infect Dis. 2018;67:1–7.
- Evaluation of a pharmacy-driven methicillin-resistant staphylococcus aureus surveillance protocol in pneumonia. Dunaway S, Orwig K, Arbogast Z, Myers ZL, Sizemore JA, Giancola SE. Int J Clin Pharm. 2018;40:526–532.
- Impact of a pharmacist-driven methicillin resistant staphylococcus aureus surveillance protocol. Willis C, Allen B, Tucker C, Rottman K, Epps K. . Am J Health Syst Pharm. 2017;74:1765–1773.
- Clinical utility of methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction assay in critically ill patients with nosocomial pneumonia. Smith MN, Erdman MJ, Ferreira JA, Aldridge P, Jankowski CA. J Crit Care. 2017;38:168–171.
- Why don’t physicians follow clinical practice guidelines: a framework for improvement. Cabana M, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. JAMA. 1999;282:1458–1465.
Source: PubMed